Filtered By:
Source: Europace

This page shows you your search results in order of date. This is page number 7.

Order by Relevance | Date

Total 183 results found since Jan 2013.

Modelling projections for the uptake of edoxaban in an European population to 2050: effects on stroke, thromboembolism, and health economics perspectives
Conclusion Our data point to a substantial increase in the human and economic cost burden of AF and so emphasize the need to reduce this burden. This may be achieved by the increased use of oral anticoagulants, particularly with the NOACs such as edoxaban.
Source: Europace - October 18, 2016 Category: Cardiology Authors: Blann, A. D., Boriani, G., Lip, G. Y. H. Tags: Atrial fibrillation Source Type: research

Yield of screening for atrial fibrillation in primary care with a hand-held, single-lead electrocardiogram device during influenza vaccination
Conclusions Screening seems feasible with an easy to use single-lead, hand-held ECG device with automatic AF detection during influenza vaccination in primary care and results in a ‘1-day’ yield of 1.1% new cases of AF. Trial registration clinicaltrials.gov NCT02006524.
Source: Europace - October 18, 2016 Category: Cardiology Authors: Kaasenbrood, F., Hollander, M., Rutten, F. H., Gerhards, L. J., Hoes, A. W., Tieleman, R. G. Tags: Atrial fibrillation Source Type: research

Cardiac arrhythmias in patients with Danon disease
ConclusionsThe present study indicates that the distinct surface ECG pattern in Danon disease is not associated with ventricular pre-excitation. Atrial fibrillation is frequently observed in these patients and may be associated with thromboembolic events in the young, while sustained ventricular arrhythmias occur less frequently than previously reported.
Source: Europace - October 14, 2016 Category: Cardiology Source Type: research

Rationale and design of AXAFA-AFNET 5: an investigator-initiated, randomized, open, blinded outcome assessment, multi-centre trial to comparing continuous apixaban to vitamin K antagonists in patients undergoing atrial fibrillation catheter ablation
Conclusion</div>The results of AXAFA-AFNET 5 will provide evidence informing about the safety of apixaban in ablation patients and on its efficacy including effects on silent brain lesions. AXAFA – AFNET 5 is an investigator-initiated trial sponsored by AFNET. The trial is supported by the DZHK (German Centre for Cardiovascular Research) and by the BMBF (German Ministry of Education and Research) and by Bristol-Myers Squibb/Pfizer Alliance.</span>
Source: Europace - October 13, 2016 Category: Cardiology Source Type: research

Cost-effectiveness of screening for atrial fibrillation in primary care with a handheld, single-lead electrocardiogram device in the Netherlands
ConclusionScreening for AF in primary care with a handheld, single-lead ECG during seasonal influenza vaccination is very likely to be cost saving for identifying new cases of AF in the Dutch population aged 65 years and over. Active screening for AF with a single-lead, handheld ECG device during seasonal influenza vaccination could be implemented in primary care.
Source: Europace - October 11, 2016 Category: Cardiology Source Type: research

Safe automatic one-lead electrocardiogram analysis in screening for atrial fibrillation
ConclusionAutomatic ECG screening using a computerized algorithm safely identifies normal ECGs in Lead I and reduces the need for manual evaluation of individual ECGs with>85% with 100% sensitivity on an individual basis.
Source: Europace - October 6, 2016 Category: Cardiology Source Type: research

Improved patient selection for cardiac resynchronization therapy by normalization of QRS duration to left ventricular dimension
ConclusionSince normalized QRSd reflects myocardial conduction properties, these findings suggest that myocardial conduction velocity rather than increased path length mainly determines response to CRT. Normalizing QRSd to LV dimension might provide a relatively simple method to improve patient selection for CRT.
Source: Europace - October 5, 2016 Category: Cardiology Source Type: research

Electrophysiological features and catheter ablation of symptomatic frequent premature atrial contractions
ConclusionsFrequent PACs in the absence of AF were characterized as having their predilection sites and longer CoIs than those inducing AF. Catheter ablation was effective to eliminate symptomatic, frequent, and drug-refractory PACs.
Source: Europace - October 4, 2016 Category: Cardiology Source Type: research

Antithrombotic therapy use in patients with atrial fibrillation before the era of non-vitamin K antagonist oral anticoagulants: the Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) Phase I cohort
Conclusion Phase I of GLORIA-AF shows that VKAs were mostly used in patients with persistent/permanent (vs. paroxysmal) AF and in those with high stroke risk. Furthermore, there were meaningful geographical differences in the use of VKA therapy in the era before the availability of NOACs, including a much lower use of VKAs in China, where most patients either received antiplatelet agents or no antithrombotic treatment.
Source: Europace - August 30, 2016 Category: Cardiology Authors: Huisman, M. V., Ma, C. S., Diener, H.-C., Dubner, S. J., Halperin, J. L., Rothman, K. J., Teutsch, C., Schoof, N., Kleine, E., Bartels, D. B., Lip, G. Y. H., for the GLORIA-AF Investigators Tags: Atrial fibrillation Source Type: research

Effectiveness and safety of dabigatran versus acenocoumarol in 'real-world patients with atrial fibrillation
Conclusion In ‘real-world’ patients with AF, dabigatran appears to be as effective, but significantly safer than acenocoumarol.
Source: Europace - August 30, 2016 Category: Cardiology Authors: Korenstra, J., Wijtvliet, E. P. J., Veeger, N. J. G. M., Geluk, C. A., Bartels, G. L., Posma, J. L., Piersma-Wichers, M., Van Gelder, I. C., Rienstra, M., Tieleman, R. G. Tags: Atrial fibrillation Source Type: research

Incidence and outcomes of cerebrovascular events complicating catheter ablation for atrial fibrillation
Conclusion Cerebrovascular complications related to catheter ablation of AF are relatively infrequent and typically occur early either during the procedure or within the first 24 h after AF ablation. Previous ischaemic stroke, mechanical valve replacement, and CHA2DS2-VASc score ≥3 are independent predictors of such complications. The majority of these events are ischaemic stroke with a benign clinical outcome, while ICH may correlate with poor prognosis.
Source: Europace - August 30, 2016 Category: Cardiology Authors: Liu, Y., Zhan, X., Xue, Y., Deng, H., Fang, X., Liao, H., Huang, J., Liu, F., Liang, Y., Wei, W., Wu, S. Tags: Ablation for atrial fibrillation Source Type: research

Percutaneous left atrial appendage occlusion: the Munich consensus document on definitions, endpoints, and data collection requirements for clinical studies
<span class="paragraphSection">The increasing interest in left atrial appendage occlusion (LAAO) for ischaemic stroke prevention in atrial fibrillation (AF) fuels the need for more clinical data on the safety and effectiveness of this therapy. Besides an assessment of the effectiveness of the therapy in specific patients groups, comparisons with pharmacological stroke prophylaxis, surgical approaches, and other device-based therapies are warranted. This paper documents the consensus reached among clinical experts in relevant disciplines from Europe and North America, European cardiology professional societies, and re...
Source: Europace - August 17, 2016 Category: Cardiology Source Type: research

Challenges in atrial fibrillation beyond stroke prevention: keeping patients out of the hospital
Source: Europace - August 4, 2016 Category: Cardiology Authors: Pokorney, S. D., Steinberg, B. A. Tags: EDITORIALS Source Type: research

Hospitalizations in patients with atrial fibrillation: an analysis from ROCKET AF
Conclusion Nearly 1 in 7 of the moderate-to-high-risk patients with AF enrolled in this trial was hospitalized within 2 years, and both AF and bleeding were rare causes of hospitalization. Further research is needed to determine whether care pathways directed at comorbid conditions among AF patients could reduce the need for and costs associated with hospitalization.
Source: Europace - August 4, 2016 Category: Cardiology Authors: DeVore, A. D., Hellkamp, A. S., Becker, R. C., Berkowitz, S. D., Breithardt, G., Hacke, W., Halperin, J. L., Hankey, G. J., Mahaffey, K. W., Nessel, C. C., Singer, D. E., Fox, K. A. A., Patel, M. R., Piccini, J. P., on behalf of the ROCKET AF Steering Com Tags: Atrial fibrillation Source Type: research

Real-world persistence and adherence to oral anticoagulation for stroke risk reduction in patients with atrial fibrillation
Conclusions Rivaroxaban and dabigatran demonstrated better persistence than VKA at Day 360. Furthermore, rivaroxaban was associated with better persistence and adherence than dabigatran. Further studies are needed to identify factors responsible for this difference and evaluate the impact on outcomes.
Source: Europace - August 4, 2016 Category: Cardiology Authors: Beyer-Westendorf, J., Ehlken, B., Evers, T. Tags: Atrial fibrillation Source Type: research